BioSpace

BioSpace
  • 0.0 (0)
  • Ciencias de la vida
  • Cada semana

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

  1. hace 5 días

    The Italian inflection point: Clinical strength, culture and capital

    In this episode of Denatured, you’ll hear from Diana Saraceni, founder and managing partner at Panakès Partners and Fabrizio Calisti, medical director at Angelini Ventures. We explore how Italy’s life sciences ecosystem has evolved over the last decade—from stronger tech transfer and growing venture capital to the gaps that still keep it from matching the UK, Germany or France in company creation and scale. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Diana Saraceni, Founder and Managing Partner, Panakès Partners Fabrizio Calisti, Medical Director, Angelini Ventures Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    The Italian inflection point: Clinical strength, culture and capital

  2. hace 6 días

    Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

    After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.

    Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

  3. hace 6 días

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

    The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

  4. 6 ago

    The next treatment-resistant depression paradigm

    In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Hans Eriksson, Chief Medical Officer, FundaMental Pharma Steve Levine, Chief Patient Officer, Compass Pathways Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    The next treatment-resistant depression paradigm

  5. 30 jul

    Life after the lead asset: Advancing an early-stage pipeline

    In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively. This episode is presented in partnership with Arvinas. Host Jennifer Smith-Parker, Director of Insights, BioSpace Guest Randy Teel, President and CEO, Arvinas

    Life after the lead asset: Advancing an early-stage pipeline

  6. 29 jul

    Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

    The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.

    Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

  7. 23 jul

    Nordic biotech’s next act: From fragmentation to global force

    In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Ester Sklarsky, Principal, Sound Bioventures João Ribas, Partner, Novo Holdings Seed Investments Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    Nordic biotech’s next act: From fragmentation to global force

  8. 22 jul

    Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

    Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.

    Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
Ver todo (256)

Acerca de

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Información

  • Creador
    BioSpace
  • Años de actividad
    2023 - 2026
  • Episodios
    256
  • Clasificación
    Apto
  • Copyright
    © 2026 BioSpace
  • Mostrar sitio web
    BioSpace

También te podría interesar